Table 1 Baseline characteristics of patients in the ARNI-continue and ARB switch-groups
Variables | Total (n = 11) | ARNI-continue group (n = 5) | ARB-switch group (n = 6) | p-value |
|---|---|---|---|---|
Age, year | 68.1 ± 10.9 | 76.6 ± 5.1 | 61.0 ± 9.3 | 0.028 |
Male gender, n (%) | 8 (73) | 3 (60) | 5 (83) | 0.333 |
Weight, kg | 67.3 ± 10.1 | 66.7 ± 3.3 | 67.8 ± 13.9 | 0.624 |
Body mass index, kg/m2 | 25.1 ± 3.8 | 25.0 ± 2.9 | 25.2 ± 4.7 | 1.000 |
Body surface area, m2 | 1.73 ± 0.12 | 1.73 ± 0.05 | 1.73 ± 0.17 | 0.621 |
Heart rate, beats/min | 69 ± 11 | 73 ± 12 | 66 ± 10 | 0.409 |
Heart rhythm disorder | ||||
Atrial fibrillation, n (%) | 3 (27) | 1 (20) | 2 (33) | 0.576 |
Pacing, n (%) | 1 (9) | 1 (20) | 0 (0) | 0.455 |
Systolic BP, mmHg | 123 ± 16 | 117 ± 18 | 128 ± 14 | 0.325 |
Diastolic BP, mmHg | 77 ± 14 | 66 ± 14 | 83 ± 7 | 0.045 |
Risk factor | ||||
Previous or current hypertension, n (%) | 6 (55) | 2 (40) | 4 (67) | 0.392 |
Previous or current DM, n (%) | 5 (45) | 4 (80) | 1 (17) | 0.067 |
Previous or current dyslipidemia, n (%) | 6 (55) | 3 (60) | 3 (50) | 0.608 |
Previous or current smoking, n (%) | 6 (55) | 2 (40) | 4 (67) | 0.392 |
NYHA class ≥ III, n (%) | 3 (27) | 1 (20) | 2 (33) | 0.576 |
Ischemic heart failure etiology, n (%) | 5 (45) | 3 (60) | 2 (33) | 0.392 |
Biochemical data | ||||
Serum creatinine, mg/dL | 1.1 ± 0.4 | 1.1 ± 0.4 | 1.2 ± 0.4 | 0.855 |
eGFR, mL/min/1.73 m2 | 54.7 ± 19.9 | 54.0 ± 25.2 | 55.4 ± 15.9 | 0.754 |
ANP (pg/mL) | 908.4 ± 635.6 | 611.6 ± 474.6 | 1155.7 ± 592.6 | 0.144 |
BNP (pg/mL) | 375.2 ± 296.7 | 195.4 ± 141.5 | 524.9 ± 311.1 | 0.100 |
NT-proBNP (pg/mL) | 1003.7 ± 753.2 | 785.8 ± 457.9 | 1185.3 ± 835.6 | 0.584 |
ARNI administration period before enrollment, months | 40 ± 17 | 29 ± 16 | 48 ± 13 | 0.062 |
Medications at enrollment | ||||
β-blockers, n (%) | 11 (100) | 5 (100) | 6 (100) | 1.000 |
Loop diuretics, n (%) | 9 (82) | 4 (80) | 5 (83) | 0.727 |
Aldosterone antagonists, n (%) | 5 (45) | 2 (40) | 3 (50) | 0.608 |
Calcium sensitizers, n (%) | 2 (18) | 2 (40) | 0 (0) | 0.182 |
SGLT-2 inhibitors, n (%) | 1 (9) | 0 (0) | 1 (17) | 0.546 |
Statins, n (%) | 7 (64) | 3 (60) | 4 (67) | 0.500 |
Antiarrhythmic drugs, n (%) | 1 (9) | 0 (0) | 1 (17) | 0.546 |
Echocardiographic data | ||||
LVEDV index, mL/m2 | 67.2 ± 29.2 | 62.3 ± 24.2 | 71.2 ± 35.0 | 0.806 |
LVESV index, mL/m2 | 39.6 ± 21.5 | 37.5 ± 21.2 | 41.3 ± 24.1 | 0.806 |
LVEF, % | 43.2 ± 11.1 | 42.8 ± 11.4 | 43.6 ± 12.2 | 1.000 |
PWTd, mm | 11.3 ± 1.5 | 11.8 ± 1.5 | 11.0 ± 1.6 | 0.451 |
PWTs, mm | 13.8 ± 2.2 | 14.5 ± 2.6 | 13.2 ± 1.8 | 0.451 |
IVSTd, mm | 10.7 ± 1.4 | 11.3 ± 1.5 | 10.2 ± 1.3 | 0.447 |
IVSTs, mm | 13.1 ± 2.0 | 13.3 ± 2.1 | 13.0 ± 2.1 | 0.898 |
LVM index, g/m2 | 139.6 ± 27.7 | 138.7 ± 35.1 | 140.0 ± 24.7 | 0.624 |